Medicure Inc. (MPH) Q3 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to Medicare's earnings conference call for the quarter ended September 30th, 2023. My name is Holly and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Before we proceed, I would like to remind everyone that this presentation contains forward-looking statements relating to future results, events, and expectations which are made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, amongst others, those described in the company's most recent annual information form and Form 20-F. Later, we will conduct a question and answer session. Please note that this conference call is being recorded and today's date is November 22nd, 2023. I would now like to turn the conference call over to Dr. Albert Friesen, Chief Executive Officer of Medicare Inc. Please go ahead, Dr. Friesen. Thank you, Holly, and good morning to everybody on the call. We appreciate your interest and participation in today's call. Joining me today on this Q3 2023 financial statement call is Dr. Neil Owens, President and Chief Operating Officer, and Horace Uden, Medicare's Chief Financial Officer. We're pleased to report that net revenue of $5.0 million for Q3 remains steady from the previous quarters, with a net income of $77,000 or more. one cent per share, an EBITDA of $628,000, all showing consistent good financial returns, particularly when you consider we're also investing $508,000 in R&D in this past quarter for the future growth potential. Agristat sales, Zipidimac sales, and Ma...